LOB International Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: LOB International Pharmaceutical Export Portfolio Dataset — 3 Products, $460.3K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

LOB International — Pharmaceutical Exporter Profile (2026) | 3 Products, $460.3K Trade | TransData Nexus

LOB International

Indian Pharmaceutical Exporter · Antimalarial & Antiparasitic Specialist · $460.3K Total Trade · DGFT Verified

LOB International is an Indian pharmaceutical exporter with a total trade value of $460.3K across 3 products in 3 therapeutic categories. Based on 99 verified export shipments from Indian Customs (DGFT) records, LOB International is the #1 Indian exporter in 1 product including Praziquantel. Top exports include Praziquantel ($400.0K), Linagliptin ($48.7K), Betadine ($11.7K).

LOB International — Export Portfolio & Destination Treemap

LOB International pharmaceutical export portfolio — 3 products across 3 therapeutic categories. Source: Indian Customs (DGFT).

Who is LOB International? — Company Overview & Market Position

LOB International is an Indian pharmaceutical exporter specializing in finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Established in 1978, the company is headquartered in Mumbai, Maharashtra, at G-6 Khira Industrial Estate, B. M. Bhargav Road, Santacruz West. The firm operates as both an importer and exporter, facilitating bidirectional trade across key categories such as pharmaceutical products, medical supplies, and consumer goods. The company's website is www.lobin.com.

LOB International's ownership structure is not publicly disclosed. The company employs a small team, with an estimated workforce of 1-10 employees. Specific financial details, including annual revenue, are not publicly available. The company's operations encompass a diverse product portfolio, including toiletries, confectionery, non-alcoholic beverages, and various consumer goods.

What Does LOB International Export? — Product Portfolio Analysis

Top Products by Export Value

1Praziquantel$400.0K 2

Product Portfolio — Top 3 by Export Value

LOB International exports 3 pharmaceutical products across 3 therapeutic categories. Market leader (#1 exporter) in 1 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Praziquantel	Antimalarial & Antiparasitic	$400.0K	8	13.7%	1
2	Linagliptin	Advanced Diabetes Medications	$48.7K	3	1.2%	7
3	Betadine	Brand Names & OTC Products	$11.7K	88	0.2%	11

LOB International exports 3 pharmaceutical products across 3 therapeutic categories with a total export value of $460.3K. The company is the #1 Indian exporter in 1 product: Praziquantel. The top category is Antimalarial & Antiparasitic (86.9% of portfolio), followed by Advanced Diabetes Medications (10.6%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

LOB International — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

LOB International does not own manufacturing facilities; instead, it operates as a trading company, sourcing products from various manufacturers. The company specializes in exporting finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Specific details regarding the manufacturing capacities and specializations of its suppliers are not publicly disclosed.

3Key Leadership

The key leadership of LOB International includes Mr. Val Lobo, who serves as the Chief Executive Officer (CEO). Specific details regarding other executive roles, such as Chief Financial Officer (CFO) or other key executives, are not publicly available. The company's leadership is focused on facilitating international trade and ensuring the quality of the pharmaceutical products it exports.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does LOB International Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

LOB International's export data indicates a significant presence in regulated markets, with a total export value of $460,000 USD across 99 shipments from 2022 to 2026. The company's product portfolio includes three pharmaceutical products across three therapeutic categories. The top three products exported are Praziquantel, Linagliptin, and Betadine, with Praziquantel being the leading product with a market share of 13.7%. The therapeutic categories include Antimalarial & Antiparasitic (86.9%), Advanced Diabetes Medications (10.6%), and Brand Names & OTC Products (2.5%). LOB International holds the #1 market leader position in Praziquantel. The company's portfolio is highly concentrated, with the top five products accounting for 100% of its exports.

2Emerging Markets

LOB International's export data does not provide specific information regarding its presence in emerging markets such as Africa, Latin America, or Southeast Asia. The company's focus appears to be on regulated markets, as indicated by its export data. Specific details about WHO prequalification or other certifications enabling access to these markets are not publicly available.

3Geographic Strategy

LOB International — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding LOB International's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, or inspection history are not publicly available. As a trading company, LOB International may not hold direct FDA approvals but could source products from manufacturers with FDA-approved facilities. However, without explicit information, it is challenging to assess the company's compliance status with the U.S. Food and Drug Administration.

2WHO & EU GMP

LOB International's export data does not provide information regarding WHO prequalification, EU Good Manufacturing Practice (GMP) certificates, or European Directorate for the Quality of Medicines & HealthCare (EDQM) status. As a trading company, LOB International may source products from manufacturers holding these certifications, but specific details are not publicly disclosed. The absence of this information makes it difficult to evaluate the company's adherence to international quality standards.

3CDSCO & Indian Regulatory

LOB International — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

LOB International operates in the competitive pharmaceutical export market, with major players such as Sun Pharmaceutical Industries Limited, Aurobindo Pharma Limited, Lupin Limited, and Dr. Reddy's Laboratories Limited. These companies have established significant market shares and global reach. LOB International's focus on a limited product portfolio, particularly in the Antimalarial & Antiparasitic category, positions it in a niche segment. While this specialization may reduce direct competition, it also limits the company's ability to leverage economies of scale and diversify its market presence.

2Key Differentiators

LOB International's key differentiator lies in its specialization in exporting Praziquantel, a leading Antimalarial & Antiparasitic product, where it holds a 13.7% market share. This focus allows the company to develop expertise and establish strong relationships within this therapeutic area. However, the company's portfolio concentration on a single product may limit its ability to adapt to changing market demands and diversify its revenue streams.

3Strategic Position

Buyer Due Diligence Brief — Evaluating LOB International as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

As a trading company, LOB International sources its pharmaceutical products from various manufacturers. The company's export data indicates a total export value of $460,000 USD across 99 shipments from 2022 to 2026, with a portfolio concentration on three products. Specific details regarding the reliability, quality standards, and compliance of its suppliers are not publicly disclosed. Potential partners should conduct thorough due diligence to assess the consistency and quality of the products supplied by LOB International.

2Certifications to Verify

Importers considering partnerships with LOB International should verify the following certifications to ensure product quality and regulatory compliance:

FDA Approval: Confirm that the products are manufactured in facilities registered with the U.S. Food and Drug Administration.

WHO-GMP Certification: Ensure that the manufacturing facilities adhere to the World Health Organization's Good Manufacturing Practices.

Frequently Asked Questions — LOB International

How many pharmaceutical products does LOB International export from India?

LOB International exports 3 pharmaceutical products across 3 therapeutic categories. The top exports are Praziquantel ($400.0K), Linagliptin ($48.7K), Betadine ($11.7K). Total export value is $460.3K.

What is LOB International's total pharmaceutical export value?

LOB International's total pharmaceutical export value is $460.3K, based on 99 verified shipments recorded in Indian Customs (DGFT) data.

In which products is LOB International the #1 Indian exporter?

LOB International is the #1 Indian exporter in 1 products: Praziquantel (13.7% market share).

What therapeutic categories does LOB International cover?

LOB International exports across 3 therapeutic categories. The largest are Antimalarial & Antiparasitic (86.9%, 1 products), Advanced Diabetes Medications (10.6%, 1 products), Brand Names & OTC Products (2.5%, 1 products).

Get Full LOB International Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.